Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IUZ5

UPID:
AT2L2_HUMAN

ALTERNATIVE NAMES:
Alanine--glyoxylate aminotransferase 2-like 2

ALTERNATIVE UPACC:
Q8IUZ5; A8K7P6; B3KN36; D3DWP9; Q8WYS6; Q96HW8

BACKGROUND:
5-phosphohydroxy-L-lysine phospho-lyase, with alternative names such as Alanine--glyoxylate aminotransferase 2-like 2, is pivotal in the catabolism of amino acids. It efficiently converts 5-phosphohydroxy-L-lysine to ammonia, inorganic phosphate, and 2-aminoadipate semialdehyde, a process vital for amino acid degradation.

THERAPEUTIC SIGNIFICANCE:
The enzyme's malfunction is associated with Phosphohydroxylysinuria, characterized by abnormal urinary metabolites. The exploration of 5-phosphohydroxy-L-lysine phospho-lyase's function offers a promising avenue for developing novel therapeutic approaches to treat or manage this metabolic anomaly.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.